An article published in Brain Journal, September 25, 2018, regarding research findings of the International Guillain Barre Outcome Survey (IGOS), partially supported by GBS|CIDP Foundation International, received the “Editor’s Choice.” Findings of IGOS are significant to the GBS community as noted in the abstract summary of articleRead More about Dr. Bart Jacobs, Vice Chairman of GMAB, and co-authors, “Editor’s Choice,” Brain Journal
In 2017, a nationwide survey of US CIDP patients was conducted to assess the impact of disease-related disability and treatment on lifestyle and work activities. Approximately 3250 individuals aged ≥18 years, recruited by the GBS|CIDP Foundation and self-reported to have CIDP, were invited to complete an online survey; of these, 475 completed the survey and…Read More about CIDP Disease Burden — Results of a US Nationwide Patient Survey
This Rare Disease Day (February 28), the GBS|CIDP Foundation will be launching an online Patient Registry for patients with GBS|CIDP or variants of the conditionRead More about New GBS|CIDP Patient Registry Launching on Rare Disease Day!
By Jeffrey A. Allen, MD Member, GBS|CIDP Foundation Global Medical Advisory Board CIDP as a named disease entity is now about 4 decades old. The laboratory data that helps define the disease, nerve conduction studies and in some cases cerebral spinal fluid and nerve biopsy, is even older; and the initial description of what has…Read More about Research in CIDP: Are we making progress?
David Saperstein, MD Co-Director GBS/CIDP Center of Excellence Phoenix Neurological Associates Phoenix, AZ Intravenous immunoglobulin (IVIg) is one of the main therapies used to treat CIDP. This therapy can be very effective but there are drawbacks. Some people experience headaches related to the intravenous infusions. Some people have difficulty with IV access. Also, the need…Read More about Subcutaneous Immunoglobulin: A Newly Approved Treatment Option for CIDP